Pfizer Inc. (NYSE:PFE) Shares Sold by Natixis Advisors LLC

Natixis Advisors LLC cut its holdings in shares of Pfizer Inc. (NYSE:PFE) by 7.8% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 2,397,900 shares of the biopharmaceutical company’s stock after selling 203,516 shares during the period. Natixis Advisors LLC’s holdings in Pfizer were worth $69,395,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. Olistico Wealth LLC purchased a new stake in shares of Pfizer in the second quarter valued at approximately $25,000. MFA Wealth Advisors LLC purchased a new stake in shares of Pfizer during the second quarter worth about $29,000. Quarry LP acquired a new position in shares of Pfizer during the 2nd quarter worth about $31,000. Financial Connections Group Inc. purchased a new position in Pfizer in the 2nd quarter valued at about $34,000. Finally, Strategic Financial Concepts LLC acquired a new stake in Pfizer in the 2nd quarter worth about $38,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have commented on the company. Wolfe Research initiated coverage on Pfizer in a report on Friday. They set an “underperform” rating and a $25.00 target price for the company. StockNews.com raised Pfizer from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, November 12th. Wells Fargo & Company lifted their target price on shares of Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 31st. Barclays increased their target price on shares of Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 31st. Finally, Evercore ISI upgraded shares of Pfizer to a “strong-buy” rating in a research report on Wednesday, October 30th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, five have issued a buy rating and three have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $32.92.

Insider Transactions at Pfizer

In other Pfizer news, Director Scott Gottlieb bought 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 30th. The shares were purchased at an average cost of $28.24 per share, with a total value of $28,240.00. Following the purchase, the director now directly owns 10,000 shares in the company, valued at approximately $282,400. This represents a 11.11 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 0.06% of the company’s stock.

Pfizer Price Performance

NYSE:PFE opened at $24.80 on Friday. Pfizer Inc. has a 52 week low of $24.48 and a 52 week high of $31.54. The stock’s fifty day moving average is $28.64 and its two-hundred day moving average is $28.66. The company has a market capitalization of $140.54 billion, a P/E ratio of 33.51, a P/E/G ratio of 0.79 and a beta of 0.67. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.42. The company had revenue of $17.70 billion during the quarter, compared to analyst estimates of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. Pfizer’s revenue was up 31.2% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.17) earnings per share. Equities analysts expect that Pfizer Inc. will post 2.96 EPS for the current year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be given a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a yield of 6.77%. The ex-dividend date is Friday, November 8th. Pfizer’s payout ratio is 227.03%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.